CACNG2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL116362	0.45	11/20
SCHEMBL2585915	0.51	8/20
SCHEMBL3354274	0.62	7/20
SCHEMBL3357851	0.54	7/20
SCHEMBL3350921	0.49	7/20
SCHEMBL619154	0.41	7/20
SCHEMBL620978	0.40	7/20
SCHEMBL621013	0.40	7/20
SCHEMBL621555	0.39	6/20
SCHEMBL617973	0.38	6/20
SCHEMBL1810921	0.51	5/20
SCHEMBL3477582	0.47	5/20
SCHEMBL3353571	0.47	5/20
SCHEMBL3248439	0.45	5/20
SCHEMBL620400	0.44	5/20
SCHEMBL620595	0.44	5/20
SCHEMBL619405	0.43	5/20
SCHEMBL3468836	0.42	5/20
SCHEMBL618375	0.37	5/20
SCHEMBL3467028	0.58	4/20

Clinical trials — most relevant to CACNG2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Effect of Pregabalin and Etoricoxib on Pain Alone Versus in Combination	PHASE4	UNKNOWN
Efficacy and Safety of Mirogabalin in Diabetic Peripheral Neuropathic Pain	PHASE4	RECRUITING
Multimodal Versus Opioid aNalgesia in carDiAc Surgery	PHASE4	COMPLETED
Role of Intralipid in Management of Organophosphorus Poisoning	PHASE2/PHASE3	WITHDRAWN
The Re-Prosper HF Study	PHASE2/PHASE3	COMPLETED
Pain and Chronic Pancreatitis - Clinical End Experimental Studies	PHASE2/PHASE3	COMPLETED
Dronabinol in Trichotillomania and Other Body Focused Repetitive Behaviors	PHASE2/PHASE3	COMPLETED
Analgesic Potentials of Preoperative Pregabalin,Magnesium Sulphate and Their Combination in Acute Post-thoracotomy Pain	PHASE3	COMPLETED
Pharmacogenetic Treatment With Anti-Glutaminergic Agents for Comorbid PTSD & AUD	PHASE3	COMPLETED
Effect of Oral Pregabalin on Spinal Neurotransmitters in Patients Undergoing Knee Replacement	PHASE3	COMPLETED
Valproic Acid (VPA) for Acute Kidney Injury (AKI) in Liver Transplant Patients	PHASE2	WITHDRAWN
Population Pharmacokinetic-pharmacodynamic (PK-PD) Modeling of Co-administered Gabapentin in Neuropathic Pain	PHASE2	COMPLETED
Valproic Acid (VPA) for Acute Kidney Injury (AKI) in Trauma Patients	PHASE2	WITHDRAWN
4-Aminopyridine in Episodic Ataxia Type 2	PHASE2	WITHDRAWN
Effect of Lidocaine Transdermal Patch as Add-On Therapy in Treatment of Oxaliplatin Induced Peripheral Neuropathy in Colorectal Cancer Patients	PHASE2	UNKNOWN
A Phase I/II, First-In-Human Trial to Evaluate the Safety, Tolerability, and Pharmacokinetic Activity to Prevent or Treat Neuropsychiatric Symptoms in Pediatric Subjects With Timothy Syndrome	PHASE1/PHASE2	NOT_YET_RECRUITING
Bioequivalence Study of Tacrolimus in Healthy Volunteers	PHASE1	COMPLETED
Pregabalin Phonophoresis and MET for Knee Osteoarthritis	nan	RECRUITING
Factors Affecting Salt Intake in Young Adults	nan	UNKNOWN
Molecular and Cellular Characterization of Cardiac Tissue in Postnatal Development	nan	RECRUITING
Genetic Determinants of Sudden Cardiac Death	nan	COMPLETED
ST-segment Elevation as an AF Endophenotype	nan	COMPLETED
Manganese-Enhanced Magnetic Resonance Imaging (MEMRI) in Ischaemic, Inflammatory and Takotsubo Cardiomyopathy (MEMORY)	nan	COMPLETED
Gene-STEPS: Shortening Time of Evaluation in Paediatric Epilepsy Services	nan	UNKNOWN
Molecular Genetic Screening and Identification of Congenital Arrhythmogenic Diseases	nan	UNKNOWN
Sodium Channel Splicing in Heart Failure Trial (SOCS-HEFT) Prospective Study	nan	UNKNOWN
Early Detection of Cardiomyopathy by Speckle Echo, High Sensitive Troponin and Cardiac Ryanodine Receptors	nan	UNKNOWN
Sodium Channel Splicing in Heart Failure Trial	nan	COMPLETED
Pre-Emptive Analgesia in Ano-Rectal Surgery	nan	COMPLETED
Evaluation of the Effects of KCNQ1 Mutation on Insulin Tolerance and Obsessive Compulsive Features in Long QT Romano-Ward Syndrome Patients.	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a CACNG2 binder may also engage these)

Protein	Name	Similarity
O88602	—	1.000	O88602 →
Q71RJ2	—	1.000	Q71RJ2 →
Q8VHX0	—	1.000	Q8VHX0 →
Q0VD05	—	0.998	Q0VD05 →
Q5R5X2	—	0.998	Q5R5X2 →
CACNG3	Voltage-dependent calcium channel gamma-3 sub	0.998	landscape →
Q4R589	—	0.998	Q4R589 →
Q9JJV5	—	0.998	Q9JJV5 →
Q8VHW9	—	0.975	Q8VHW9 →
CACNG4	Voltage-dependent calcium channel gamma-4 sub	0.972	landscape →
Q4V922	—	0.968	Q4V922 →
Q3SZX0	—	0.968	Q3SZX0 →
Q5VW38	—	0.968	Q5VW38 →
Q9JJV4	—	0.968	Q9JJV4 →
Q9H2E6	—	0.967	Q9H2E6 →
Q7ZWN9	—	0.967	Q7ZWN9 →
W5P3P0	—	0.967	W5P3P0 →
Q16625	—	0.966	Q16625 →
P22831	—	0.966	P22831 →
F6QZ15	—	0.966	F6QZ15 →
Q9NV29	—	0.966	Q9NV29 →
Q8R310	—	0.966	Q8R310 →
Q8R1W2	—	0.965	Q8R1W2 →
Q7Z2D5	—	0.965	Q7Z2D5 →
Q148L1	—	0.965	Q148L1 →
Q923Z0	—	0.965	Q923Z0 →
Q569C0	—	0.965	Q569C0 →
Q7TME0	—	0.965	Q7TME0 →
Q6DFT4	—	0.965	Q6DFT4 →
O42582	—	0.965	O42582 →